Health Canada has announced the labeling update for all cholesterol-lowering drugs (statins).
The update warns about the risk of increased blood sugar levels and an increased risk of diabetes among patients with pre-existing risk factors for diabetes including high levels of glucose or triglycerides, obesity or high blood pressure.
The label update includes new warning regarding increased blood sugar levels and the risk of diabetes and how to identify high-risk patients.
Warnings are added to the drug labels for the six statins currently marketed in Canada atorvastatin (Lipitor and generics), lovastatin (Mevacor and generics), rosuvastatin (Crestor and generics), simvastatin (Zocor and generics), pravastatin (Pravachol and generics), fluvastatin (Lescol and generics).
